Drug Profile
Research programme: cancer immuno-therapeutics - Avipep
Alternative Names: ADC-AVP04; ADC-AVP06; Avibody™Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Avipep
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Cancer in Australia (IV)
- 17 Apr 2015 Early research in Cancer in Australia (IV)